Clinical trial · Observational
Predictive and Prognostic Value of Inflammatory Markers and microRNA in Stage IV Colorectal Cancer
NCT04149613CI-TRIAL-00079322unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study investigates the predictive and prognostic values of inflammatory markers and microRNA in stage IV colorectal cancer. The expression of inflammatory markers and microRNA in plasma will be correlated with tumor location, with dietary patterns and with survival during treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer Stage IV | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Colorectal Cancer Patients
- description
- Newly diagnosed stage IV colorectal cancer patients
- label
- Controls
- description
- cancer free
Primary outcomes (2)
- measure
- Level of inflammatory markers
- timeFrame
- At diagnosis before chemotherapy
- description
- Level of C-reactive protein (CRP), Erythrocyte sedimentation rate (ESR), serum albumin, fibrinogen, haptoglobin, lymphocyte monocyte ratio (LMR), neutrophil lymphocyte ratio (NLR) and platelets lymphocytes ratio (PLR)
- measure
- microRNA expression Level
- timeFrame
- At diagnosis before chemotherapy
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Newly diagnosed Stage IV colorectal cancer 2. Treatment naïve 3. For the control group: adult individuals (above 18 years) with no cancer disease Exclusion Criteria: Any disease or condition that may alter the inflammatory and immune status of subjects at baseline, such as: 1. Diagnosis of inflammatory bowel disease such as ulcerative colitis and crohn's disease. 2. Diagnosis of active systemic autoimmune disease 3. Chronic / recent use of corticosteroids 4. Use of immunosuppressant drugs
References
Publications (0)
Data not yet available
No reference posted for this study.